Idorsia Takes Bold Steps in Annual Report 2024
Ad hoc announcement pursuant to Art. 53 LR
Idorsia Ltd (SIX: IDIA) proudly announces the release of its Annual Report 2024, a comprehensive document integrating the Business Report, Governance Report, Compensation Report, Sustainability Report, and Financial Report.
Shareholders are reminded that the Annual General Meeting (AGM) will be convened to discuss the Annual Report for the year ending December 31, 2024.
Registered shareholders holding at least 0.5% of the company's share capital are encouraged to submit proposals for the AGM agenda. Suggestions must reach Idorsia Ltd's Corporate Secretary by the specified deadline.
To participate in the AGM, shareholders must ensure they are registered by the designated date.
Key Financial Events and Developments
In 2024, Idorsia has laid out several key financial reporting dates, including the release of the First Quarter 2025 Financial Results, the AGM, and the Half-Year 2025 Financial Results.
Letter from the Chairman
Dear Shareholders,
As the new Chairman, I want to express my gratitude for your trust in me. Our 2024 achievements reflect significant progress on multiple fronts. Notably, we've seen accelerating sales of QUVIVIQ across Europe, a promising new addition to insomnia treatments.
QUVIVIQ has been highlighted in the European Sleep Research Society’s guidelines as a significant advancement in insomnia pharmacotherapy. The product’s efficacy and safety have been well-documented, reinforcing our commitment to quality patient care.
Furthermore, our treatment aprocitentan has received approval for uncontrolled hypertension, offering new hope to patients battling this condition. This first-in-class medication, easy to prescribe, is aimed at making a real difference in patient management.
Strategic Partnerships and Growth
As Idorsia continues to grow, we are actively seeking partnerships to fund product launches and develop our pipeline. In 2024, we licensed selatogrel and cenerimod to Viatris, representing a collaborative effort to enhance our R&D capabilities while securing vital milestones for our stakeholders.
The dedication of our management and board has led us through challenging times, focusing on securing partnerships that will yield maximum value for our innovations.
CEO Insights on Progress and Future Directions
Dear Shareholders,
As I step into my role as CEO, I've been met with immense talent and commitment within our global team. Reflecting on the past year, our primary objective remains to keep Idorsia operational while pursuing valuable partnerships.
Key developments include entering a global agreement with Viatris for the joint development of selatogrel and cenerimod, which ensures continued progress while protecting shareholder value.
Despite some setbacks with aprocitentan, we are optimistic as we seek alternative paths to maximize its potential. Our sales performance for QUVIVIQ has been promising, especially in the EUCAN region, where we've witnessed the distribution of over 15 million tablets, helping many achieve improved sleep quality.
Innovation and Development Focus
In the U.S., we aim to adapt our marketing strategies to drive QUVIVIQ's sales and elevate awareness among practitioners. Additionally, the approval of TRYVIO marks a crucial milestone in our commitment to addressing resistant hypertension.
Our research and development strategy has been streamlined to enhance focus and efficiency. Projects are being rigorously prioritized to maximize impact while ensuring we maintain financial sustainability.
Idorsia’s Vision for the Future
With a robust pipeline and exciting partnerships, Idorsia is positioned for significant milestones in the coming years. Our goal remains clear: to become financially sustainable, achieving profitability with QUVIVIQ by 2026.
Our commitment to pushing the boundaries of medical science will continue to guide our path forward. I am grateful for your unwavering support as we work together to transform patient care and uphold our vision at Idorsia.
Sincerely,
André C. Muller
Chief Executive Officer
Frequently Asked Questions
What is the main focus of Idorsia's Annual Report 2024?
The Annual Report outlines Idorsia's accomplishments, financial results, and future strategies, highlighting advancements in products like QUVIVIQ and aprocitentan.
How does Idorsia plan to achieve commercial profitability?
Idorsia aims to achieve commercial profitability with QUVIVIQ by 2026 through strategic partnerships and optimized marketing efforts.
What are the key partnerships established by Idorsia?
Idorsia has partnered with Viatris for the development of selatogrel and cenerimod to enhance research and development efforts.
What is the significance of aprocitentan for Idorsia?
Aprocitentan addresses uncontrolled hypertension, offering a new treatment option and targeting a previously unaddressed pathway in chronic hypertension.
What are the expectations for QUVIVIQ in the EUCAN region?
QUVIVIQ has shown strong sales growth and is expected to solidify a leading position in the EUCAN region for insomnia treatment.
